Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: ICON
Ticker:iclr
Yahoo Beta:0.49
Industry:biotechnology and drugs

Company Description:  ICON plc is a contract research organization that supports phase 1 through phase 4 clinical trials for new drugs. ICON, the number 4 CRO world-wide, is based in Ireland.

Purchase Date:03 Feb 2005 Sale Date:26 Mar 2015
Purchase Price:$33.95 Sale Price:$69.25
  --Split Adjusted:$8.48  --Split Adjusted:$17.31
Shares Purchased:75 Shares Sold:80
  --Split Adjusted:300  --Split Adjusted:20
Transaction Fee:$64.85 Transaction Fee:$2.63
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$45.29 High$0.00
Date18 Jul 2004 Date01 Jan 1996
Low$31.04 Low$0.00
Date08 Oct 2004 Date01 Jan 1996
S&P (Purchase Date):$1,189.89 S&P (Sale Date):$2,056.15

Purchase
Timing:  The stock was purchased close to its six month low.
Reason:  Drug companies are increasing the amount of clinical testing outsourced to CROs. ICON has a unique, dedicated team approach to testing which appears to be reflected in higher margins and an increasing market share.

Sale
Timing:  0
Reason:  We sold some of our holdings in order to limit ICON exposure to 10% of the total portfolio value.

S&P Gain: 72.8 % Annualized Gain: 5.59%
Stock Gain: 716.63 % Annualized Gain: 23.23%

Dividends:$0.00
Net Holding Return ($): $4,794.12
Net Holding Return (%): 645.02 %